In 2025, the Nanobioelectronics and Biosensors Group consolidated a balanced portfolio of European, international and national projects. The year was marked by the successful completion of several ongoing initiatives, continued progress in strategic projects linked to point-of-care diagnostics, sustainable nanosensing and printed electronics, and the launch of new activities that reinforce the group’s scientific and translational pipeline.

Several projects reached completion during the year, including EMERGE (Emerging Printed Electronics Research Infrastructure), NANOANAEMIA (Multiplexed nanobiosensor for the instantaneous diagnosis and classification of anaemia at the point of care), GLEBIOASSAY (multiplexed point-of-care nanobiosensing for monitoring naxitamab-based immunotherapy in neuroblastoma), PAPYRUs (Polymerase Amplification combined into a Paper-based electrochemical lateral flow array for antimicrobial resistance quantification), and RATIONAL (ultRafast ChemicAl SinTerIng Of priNted nAnoparticles fiLms). These completed projects strengthened the group’s expertise in printed and paper-based sensing, clinical point-of-care diagnostics and translational nanobiosensor development.

The group continued its participation in MICROBPREDICT (Microbiome-based biomarkers to predict decompensation of liver cirrhosis and treatment response), which aims to develop personalised strategies to prevent and treat decompensated cirrhosis and acute-on-chronic liver failure by investigating the human gut microbiome. SUSNANO also continued as a Horizon Europe Twinning project with UP/CATRIN (Czech Republic), focused on boosting the scientific excellence and innovation capacity of Universiteti i Tiranës (UT) in sustainable nanosensors for water pollution detection and contributing to the development of the NANOBALKAN research centre. The group also progressed in 2D-BioPAD (Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease), and in ScreenEC (Development of a non-invasive IVD for endometrial cancer screening in high-risk populations), developed in collaboration with MIMARK, a Vall d’Hebron spin-off company. In addition, the group maintained its contribution to Know4Nano, an EU-funded Twinning project involving ICN2, CNR (National Research Council, Italy) and the University of Chemistry and Technology Prague (Czech Republic), aimed at strengthening the excellence in research and technology transfer of the BioSense Institute in Serbia.